Genryzon Red Flag Monitoring

---
name: genryzon-red-flag-monitoring
description: Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).
---

# Genryzon Red-Flag Monitoring

Safety net for a child already on somatrogon. Walk this scan at every follow-up visit and any time the family reports a new symptom.

---

## Step 1 — Symptom-triggered scan at every visit

Ask the family (and the child directly if age-appropriate) about **each** of the following since the last visit. Any positive → move to the matching Step 2 workup.

| Symptom | Suspect |
|---|---|
| Persistent headache; vision changes; nausea/vomiting; papilloedema | **Benign intracranial hypertension** |
| New limp; hip pain; knee pain (referred from hip) | **Slipped capital femoral epiphysis (SCFE)** |
| Severe or persistent abdominal pain | **Pancreatitis** |
| Localised injection-site myalgia; disproportionate pain at injection sites | **Myositis (m-cresol excipient)** |
| Back curvature progression; asymmetry of shoulders/hips; scoliosis on inspection | **Scoliosis progression** |
| New neurological symptom in a childhood cancer survivor with prior cranial radiation | **Second neoplasm (esp. meningioma)** |
| Polyuria, polydipsia, weight loss, or rising HbA1c | **Somatrogon-induced hyperglycaemia** |
| Fatigue, hypotension, weight loss, hypoglycaemia, hyponatraemia | **Unmasked central hypoadrenalism** |
| Fatigue, cold intolerance, constipation, poor growth despite therapy | **Unmasked central hypothyroidism** |
| New hypersensitivity: rash, angioedema, wheeze, anaphylaxis | **Systemic hypersensitivity** |

---

## Step 2 — Specific workup and immediate action per red flag

### Benign intracranial hypertension (IH)

**Workup:**
- Fundoscopy — look for papilloedema
- Neurological exam
- CT/MRI brain to exclude a mass
- If exam consistent with IH → LP for opening pressure (per neurology)

**Action:**
- **Temporarily discontinue somatrogon**
- Refer to neurology / neuro-ophthalmology
- Restart cautiously **only after resolution**, with close monitoring. There is no consensus rule for restart timing; document the joint decision with neurology

### Slipped capital femoral epiphysis (SCFE)

**Workup:**
- Urgent hip / knee X-ray (AP and frog-lateral of both hips)
- Refer to paediatric orthopaedics

**Action:**
- **Non-weight-bearing** until orthopaedic review — SCFE can worsen with continued weight-bearing
- Somatrogon can generally be continued once SCFE is managed, but discuss with orthopaedic team

### Pancreatitis

**Workup:**
- Serum lipase and amylase
- Ultrasound / CT abdomen if levels elevated or persistent pain
- Look for other precipitants (gallstones, hypertriglyceridaemia, drugs)

**Action:**
- **Hold somatrogon** during acute episode
- Standard pancreatitis management (fluids, pain control, NPO if severe)
- Restart only after full resolution, with careful monitoring

### Injection-site myositis (m-cresol)

**Workup:**
- Clinical assessment — disproportionate pain, tenderness, swelling at injection sites
- CPK if diffuse myalgia
- MRI of affected muscle if severe or persistent

**Action:**
- **Switch to a metacresol-free growth hormone product** (m-cresol is the preservative in Genryzon)
- Local supportive care

### Scoliosis progression

**Workup:**
- Adam's forward bend test
- Standing spinal X-ray (Cobb angle)
- Refer to paediatric orthopaedics / spinal team if Cobb ≥20° or rapid progression

**Action:**
- Somatrogon can generally be continued — GH does not directly cause scoliosis but rapid growth may reveal or worsen it
- Manage the scoliosis per orthopaedic protocol (bracing, surgery as indicated)

### Second neoplasm — childhood cancer survivors

**Focus on:**
- **Cranial radiation history → meningioma** is the most-reported second tumour on GH
- **New neurological symptom, headache, cranial nerve deficit, focal deficit** → MRI brain
- Any suspicious skin or somatic lump → biopsy per oncology

**Action:**
- **Loop oncology in early** for any concerning symptom
- Adhere to the survivor's baseline surveillance schedule
- If second neoplasm is confirmed → **discontinue somatrogon** and manage the neoplasm

### Somatrogon-induced hyperglycaemia

**Workup:**
- Fasting plasma glucose + HbA1c
- OGTT if borderline

**Action:**
- **Diabetes at diagnosis** → involve paediatric diabetologist; escalate insulin/OAD as needed. Somatrogon can usually continue but with tight glucose monitoring
- **Pre-diabetes** → lifestyle intensification, monitor more frequently
- **Insulin-treated child already** → up-titrate insulin doses as needed

### Unmasked central hypoadrenalism

**Workup:**
- Morning cortisol
- ACTH stimulation test / ITT if borderline

**Action:**
- **If adrenal crisis suspected → treat as adrenal crisis first**: IV hydrocortisone, IV fluids, glucose. Investigate afterwards
- **If confirmed central hypoadrenalism** → start (or escalate) hydrocortisone replacement. Continue somatrogon
- **If child already on hydrocortisone replacement** → dose may need to be **increased** on GH (GH ↓ cortisone→cortisol conversion)

### Unmasked central hypothyroidism

**Workup:**
- TSH + free T4 (interpret carefully — in central hypothyroidism, TSH may be normal or inappropriately low despite low fT4)

**Action:**
- **Start or up-titrate levothyroxine** — untreated hypothyroidism blunts response to GH
- Recheck TFTs 6–8 weeks after any thyroxine change

### Systemic hypersensitivity

**Action:**
- **Immediately discontinue Genryzon**
- Standard anaphylaxis management (adrenaline IM, airway support, IV fluids, corticosteroids, antihistamines)
- **Do not rechallenge** — switch to a somatrogon-free growth hormone product after specialist review

---

## Step 3 — Scheduled monitoring at every 6–12 month visit (more often in puberty)

Even without new symptoms, at each planned visit check:

- **Auxology:** height, weight, height velocity (cm/yr), BMI
- **Bone age** — annually or as indicated
- **Tanner stage**
- **IGF-1** (day 4 post-dose — see `genryzon-igf1-titration`)
- **TSH + free T4**
- **Fasting glucose ± HbA1c**
- **Fundoscopy** if any suspicious symptom
- **Spinal inspection** for scoliosis
- **Pubertal progression** and, in girls, review of oral estrogen / OCP use

---

## Guardrails

- **Headache in a child on somatrogon is intracranial hypertension until proven otherwise** — do not attribute to common causes without a fundoscopy
- **Any limp or hip/knee pain in a child on GH warrants a same-week hip X-ray for SCFE** — this diagnosis is regularly missed and delayed diagnosis worsens the outcome
- **Injection-site myalgia is not "normal soreness"** — it can be m-cresol myositis and mandates a switch of GH product
- **Childhood cancer survivors on GH need active surveillance for second neoplasm** — a neurological complaint is never "just growing pains" in this group
- **Adrenal crisis can present as vague fatigue and abdominal pain** — a low threshold for morning cortisol / stress-dose steroids in any child on GH who becomes unwell
- **Never dismiss papilloedema on baseline fundus and continue GH** — that's a signal that pre-existing IH was missed and now the drug will worsen it
- **Somatrogon does not need to be permanently stopped for most of these events** — most can be resumed after the underlying issue is addressed, except confirmed second neoplasm and severe hypersensitivity, which are absolute stops

---

## Related MD2SKILL skills

- `genryzon-prescribing-guide` — starting dose, injection technique, monitoring cadence
- `genryzon-igf1-titration` — how to interpret and act on IGF-1 SDS
- `genryzon-pretreatment-screening` — baseline work-up before first dose
- `genryzon-drug-interactions` — glucocorticoid, insulin, thyroxine, oral estrogen adjustments
- `genryzon-treatment-discontinuation` — when to stop growth hormone entirely

---

## Source

Pfizer Products India Pvt. Ltd. **GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India).** LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.4 "Special Warnings and Precautions for Use" and Section 4.8 "Undesirable Effects".